DexCom (DXCM) reported $1.04 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 12.5%. EPS of $0.32 for the same period compares to $0.32 a year ago.The reported revenue represents a surprise of +1.99% over the Zacks Consensus Estimate of $1.02 billion. With the consensus EPS estimate being $0.33, the EPS surprise was -3.03%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expec ...

DexCom (DXCM) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.03%. A quarter ago, it was expected that this medical device company would post earnings of $0.50 per share when it actually produced earnings of $0.45, delivering a surprise of -10%.Over the last four quarters, the comp ...

Financial Performance - Revenue for the three months ended March 31, 2025, was $1.04 billion, up 12% from $921 million in the same period in 2024[110] - Gross profit for the same period was $589 million, representing a 5% increase from $561.9 million in the prior year[110] - Operating income increased by 32% to $133.7 million compared to $101.1 million in the first quarter of 2024[110] - Net income decreased by 28% to $105.4 million, down from $146.4 million in the same period last year[110] - Disposable sensor and other revenue comprised approximately 96% of total revenue for the three months ended March 31, 2025, compared to 93% in the same period in 2024[121] Customer Growth - The company added approximately 500,000 - 600,000 net customers in 2024, excluding Stelo customers, contributing to revenue growth[121] Expenses - Research and development expenses increased by $10.2 million due to higher compensation and related costs from headcount growth[122] - Selling, general and administrative expenses decreased by $22.7 million primarily due to lower legal expenses related to a settled patent infringement lawsuit[122] Cash and Liquidity - The company ended the first quarter of 2025 with cash, cash equivalents, and short-term marketable securities totaling $2.70 billion[110] - As of March 31, 2025, the company had $2.70 billion in cash, cash equivalents, and short-term marketable securities, an increase of $122.0 million from $2.58 billion as of December 31, 2024[128][144] - For the three months ended March 31, 2025, the company reported positive cash flows from operating activities of $183.8 million, a decrease of $25.4 million compared to $209.2 million for the same period in 2024[129][146] - The company expects existing cash and short-term investments, along with future cash flows, to be sufficient to fund ongoing core business operations for at least the next 12 months[135] Capital Expenditures - The company anticipates significant capital expenditures for the next year, particularly for the build-out of its manufacturing facility in Ireland, resulting in a $30.1 million increase in capital expenditures[133][146] Financial Ratios - As of March 31, 2025, the company had a working capital ratio of 1.50 and a quick ratio of 1.27, indicating sufficient current assets to cover short-term liabilities[133] - The company reported a debt-to-assets ratio of 0.36, indicating that total assets are more than sufficient to cover both short-term and long-term debts[136] Debt and Financing - The company had outstanding senior convertible notes classified as current, maturing in November 2025, and long-term notes maturing in May 2028, with potential for conversion into cash and/or shares prior to maturity[134][137] - The company received net proceeds of $1.19 billion from the 2025 Notes offering and $1.23 billion from the 2028 Notes offering, with plans to use the proceeds for general corporate purposes and potential acquisitions[130] - As of March 31, 2025, the company had no outstanding borrowings under its Amended Credit Agreement, with a total available balance of $192.3 million[132] Risk Factors - The company is exposed to foreign currency exchange risk as it expands its international operations, which may impact financial performance[127] Future Developments - Future product development plans include technologies focused on improved performance and intelligent insulin administration[102]

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1,036 million for Q1 2025, a 12% increase compared to $921 million in Q1 2024, with organic revenue growth of 14% [18] - U.S. revenue totaled $751 million, up 15% from $653 million in Q1 2024, driven by strong new customer demand [19] - International revenue grew 7% to $286 million, with organic growth of 12% [21] - Gross profit was $596.2 million, representing 57.5% of revenue, down from 61.8% in Q1 2024 [23] - Operating income was $143.1 million, or 13.8% of revenue, compared to $140.2 million in the same quarter of 2024 [24] - Adjusted EBITDA was $230.4 million, or 22.2% of revenue, compared to $220.9 million, or 24% of revenue in Q1 2024 [25] - Net income for Q1 was $127.7 million, or $0.32 per share [26] Business Line Data and Key Metrics Changes - The company experienced record levels of new customer demand, particularly from the Type 2 non-insulin using population [9][10] - The introduction of Stello, the first over-the-counter CGM, and broader access in the Type 2 market contributed to increased customer starts [10][12] - The company launched a 180-day data look-back feature for the Stello app, enhancing customer experience [13] Market Data and Key Metrics Changes - The company secured access at two of the three largest PBMs for diabetes patients, which is expected to cover nearly six million people with Type 2 diabetes by the end of the year [10][11] - International business showed strength in Japan and France, with continued growth in the Type 2 landscape [22] Company Strategy and Development Direction - The company is focused on expanding coverage for Type 2 diabetes patients and enhancing customer experience through technology and software updates [10][12] - The introduction of the 15-day G7 system is expected to set a new industry standard for sensor accuracy and wear time [16] - The company is committed to addressing FDA concerns following a warning letter and is working on corrective actions [15][102] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply dynamics and maintaining customer care during the transition period [6][19] - The company reaffirmed its revenue guidance of $4.6 billion for the year, representing 14% growth, while adjusting gross margin guidance to approximately 62% [27][29] - Management is optimistic about the potential for broader Type 2 coverage and the positive reception of CGM technology in the healthcare landscape [10][110] Other Important Information - The company announced a $750 million share repurchase program, reflecting strong cash flow and financial position [26] - Management highlighted the importance of evidence-based data in driving changes to standards of care and expanding access globally [11] Q&A Session Summary Question: Did supply have any impact on the revenue growth? - Management indicated that supply dynamics were normalized by the end of the quarter, and strong new patient performance was observed despite previous challenges [35] Question: Why is full-year guidance unchanged despite strong Q1 growth? - Management stated that it is prudent to wait and see how the year unfolds before adjusting guidance, emphasizing the importance of a full-year perspective [42] Question: What are the trends in Type 2 patient utilization and reorder rates? - Management reported good retention and utilization rates among Type 2 patients, particularly those with reimbursement coverage [50] Question: How exposed is the company to a potential recession? - Management believes the company is well-positioned to weather economic downturns due to the cost-saving benefits of its products [58][60] Question: What is the status of the FDA warning letter? - Management confirmed that the warning letter does not restrict new submissions or approvals and that they are making progress in addressing FDA concerns [102] Question: What is the timeline for the RCT data readout for Type 2 non-insulin users? - Management anticipates finishing enrollment in the first half of the year, with initial data readout expected late this year or early next year [112]

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1,036 million for Q1 2025, a 12% increase compared to $921 million in Q1 2024, with organic revenue growth of 14% [20][21] - U.S. revenue totaled $751 million for Q1 2025, up 15% from $653 million in Q1 2024 [21] - International revenue grew 7% to $286 million, with international organic revenue growth at 12% for the first quarter [24] - Gross profit was $596.2 million, representing 57.5% of revenue, down from 61.8% in Q1 2024 [26] - Operating income was $143.1 million, or 13.8% of revenue, compared to $140.2 million in the same quarter of 2024 [27] - Net income for Q1 was $127.7 million, or $0.32 per share [28] Business Line Data and Key Metrics Changes - The company experienced record new customer demand, particularly from the Type 2 non-insulin using population, indicating strong growth in this segment [10][11] - The introduction of Stello, the first over-the-counter CGM, and the CELLo biosensor has attracted a wide range of new customers [14][15] - The company is focusing on expanding its commercial reach and enhancing customer experience through software updates and broader distribution [15][16] Market Data and Key Metrics Changes - The company secured access at two of the three largest PBMs for diabetes patients, which is expected to cover nearly six million people with Type 2 diabetes by the end of the year [12][13] - International business showed strength in Japan and France, with continued growth in the DexCom One platform [25] Company Strategy and Development Direction - The company aims to build on momentum through targeted awareness campaigns and advocating for broader Type 2 coverage [12] - The introduction of new technologies and broader access is a key focus, with plans to launch the fifteen-day G7 system in the second half of the year [18][19] - The company is committed to addressing FDA recommendations following a warning letter and is working on corrective actions [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply dynamics and maintaining customer support during transitions [9][10] - The company is optimistic about future growth, reaffirming its revenue guidance of $4.6 billion for the year, representing 14% growth [29] - Management highlighted the importance of evidence in driving changes to standards of care and unlocking broader access globally [13] Other Important Information - The company announced a $750 million share repurchase program, reflecting confidence in its financial position [28] - Management emphasized the importance of operational efficiency and investments in technology to support growth [100][101] Q&A Session Summary Question: Did supply have any impact on the revenue growth? - Management indicated that they exited the quarter with normal supply levels, and the revenue figures reflect a normalized pattern [38] Question: Why is the full year guidance unchanged despite strong Q1 growth? - Management stated that it is early in the year, and they want to see how the rest of the year unfolds before making changes to guidance [45] Question: What are the trends in Type 2 patient utilization and reorder rates? - Management noted good retention rates in the Type 2 population, particularly with reimbursement, and strong utilization among Stellar users [53][54] Question: How exposed is the company to a potential recession? - Management believes they are well-positioned to weather economic downturns due to the cost-saving benefits of their products [62][64] Question: What is the status of the fifteen-day sensor rollout? - Management confirmed that they are working on compatibility with pump partners and securing coverage for the new product [92][93] Question: What is the path for Medicare coverage for non-insulin using Type 2 patients? - Management is actively working with CMS for approval and gathering evidence to support their case [116][119]

Dexcom Dexcom earnings Q1 2025 niabetes Nasdag Safe harbor statement Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "targets," "guidance," "expects," "intends, ""may," "plans," "potential," "predicts, " "prospects, " "should," "will," "would" or similar expressions and the negatives of those terms, although not all forward-looking statements contain these identifying words. Forwa ...

Revenue Performance - In Q1 2025, Dexcom reported worldwide revenue of $1.036 billion, a 12% increase from $921 million in Q1 2024[4] - U.S. revenue grew 15% year-over-year to $750.5 million, while international revenue increased by 7% to $285.5 million[24] - Total revenue for the three months ended March 31, 2025, was $1,036.0 million, representing a year-over-year growth of 12% compared to $921.0 million in 2024[26] - Sensor and other revenue increased to $997.2 million, a 17% growth year-over-year, accounting for 96% of total revenue[26] - Hardware revenue decreased to $38.8 million, reflecting a decline of 42% year-over-year, making up 4% of total revenue[26] Profitability Metrics - GAAP gross profit for Q1 2025 was $589 million, representing 56.9% of revenue, down from 61.0% in Q1 2024[4] - Non-GAAP gross profit was $596.2 million, or 57.5% of revenue, compared to 61.8% in Q1 2024[5] - GAAP operating income was $133.7 million, or 12.9% of revenue, up from $101.1 million, or 11.0% of revenue, in Q1 2024[7] - GAAP net income for Q1 2025 was $105.4 million, down from $146.4 million in Q1 2024, while non-GAAP net income was $127.7 million compared to $128.2 million[28] - Adjusted EBITDA for the three months ended March 31, 2025, was $230.4 million, an increase from $220.9 million in the same period last year[27] - GAAP diluted net income per share for Q1 2025 was $0.27, down from $0.36 in Q1 2024, while non-GAAP diluted net income per share remained stable at $0.32[28] Financial Management - Dexcom's cash and cash equivalents totaled $2.70 billion as of March 31, 2025, providing significant financial flexibility[10] - The company announced a $750 million share repurchase program alongside its Q1 results[3] - Interest expense decreased to $(23.8) million in Q1 2025 from $(31.7) million in Q1 2024, indicating improved financial management[27] Future Outlook - The company expects 2025 revenue to reach approximately $4.60 billion, reflecting a 14% growth[6] - Non-GAAP operating margin is projected to be around 21% for 2025[6] Product Development - Dexcom received FDA clearance for the Dexcom G7 15 Day System shortly after the end of the quarter[5] Investment Performance - The company reported a loss from equity investments of $4.2 million in Q1 2025, with no such loss reported in Q1 2024[27] Operational Focus - The company continues to focus on organic revenue growth and has excluded certain non-recurring items from its non-GAAP financial measures to provide clearer insights into operational performance[30][34]

The upcoming report from DexCom (DXCM) is expected to reveal quarterly earnings of $0.33 per share, indicating an increase of 3.1% compared to the year-ago period. Analysts forecast revenues of $1.02 billion, representing an increase of 10.3% year over year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Before a company reveals its ea ...

Core Viewpoint - DexCom, Inc. is set to release its first-quarter 2025 results on May 1, with expectations of revenue growth and potential challenges ahead [1][3][4]. Financial Performance - The Zacks Consensus Estimate for revenues is $1.02 billion, reflecting a 10.3% increase from the previous year [3]. - The consensus estimate for earnings is 33 cents per share, indicating a 3.1% year-over-year growth [3]. - In the last reported quarter, DexCom's earnings missed estimates by 10% but outperformed in three of the last four quarters, with an average surprise of 5.86% [1]. Market Dynamics - DexCom's performance is bolstered by an expanded U.S. prescriber base and improved coverage by major pharmacy benefit managers (PBMs) [5]. - The company has seen a record number of new patient starts and added 50,000 new clinicians in 2024, indicating strong commercial execution [6]. - U.S. revenues improved by 4% year-over-year in the fourth quarter, following a decline in the third quarter [7]. International Expansion - The international segment grew by 17% year-over-year in the last quarter, driven by the launch of G7 in Australia and coverage for Dexcom ONE+ in France and New Zealand [7][8]. - The return to growth in Japan, aided by a new sales structure, is a significant highlight [8]. Product Development - Stelo, an over-the-counter continuous glucose monitor, has gained traction with over 140,000 users in its first four months [8]. - DexCom plans to enhance Stelo's adoption through product iterations and partnerships, including integration with Oura Ring for comprehensive health monitoring [9]. Financial Outlook - DexCom projects full-year 2025 revenue of $4.6 billion, representing organic growth of 14% [10]. - The company anticipates continued margin improvement as it converts its installed base to G7 and scales manufacturing [10]. - DexCom holds a strong cash position of $2.58 billion, providing financial flexibility for strategic initiatives [11].

SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and ...